These Analysts Boost Their Forecasts On Johnson & Johnson After Upbeat Q3 Earnings
1. JNJ reported Q3 earnings of $2.80, beating expectations. 2. Sales rose to $23.99 billion, above consensus estimates. 3. 2025 earnings guidance affirmed, sales guidance raised. 4. Plans to separate Orthopedics business announced. 5. Analysts adjusted price targets, maintaining strong outlook.